event search / formoterol products / online version / age / device / combination device / /
MedicalCondition
New Zealand asthma mortality epidemics / catastrophic asthma / pediatric asthma / MS / chronic asthma / asthma / Research KEY WORDS asthma / serious asthma / composite asthma / severe asthma / No. of cases Asthma / /
MedicalTreatment
concomitant therapy / pharmacotherapy / /
Organization
Food and Drug Administration / Pediatric Advisory Committee / Division of Epidemiology / Division of Biometrics / Drug Safety and Risk Management Advisory Committee / Pulmonary-Allergy Drugs Advisory Committee / FDA / American Academy of Pediatrics / American Academy of Pediatrics FINANCIAL DISCLOSURE / Center for Drug Evaluation / /
Person
Palmer J. Serevent / S. Levenson / Arch Pediatr Adolesc Med / Silver Spring / Dianne Murphy / Dianne Murphy Pediatrics / Bradley W. McEvoy / Ann W. McMahon / Andrew D. Mosholder / W. McMahon / D. Mosholder / Mark S. Levenson / Ann Intern / / /
ARTICLES Age and Risks of FDA–Approved Long-Acting 2-Adrenergic Receptor Agonists AUTHORS: Ann W. McMahon, MD, MS,a Mark S. Levenson, PhD,b Bradley W. McEvoy, DrPH,b Andrew D. Mosholder,